Allergy Therapeutics (LON:AGY) Hits New 12-Month Low – What’s Next?

Allergy Therapeutics plc (LON:AGY) shares hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as GBX 3.97 and last traded at GBX 4.20, with a volume of 523,405 shares traded. The stock had previously closed at GBX 4.25.

Allergy Therapeutics Stock Down 6.2%

The company has a market cap of £237.47 million, a P/E ratio of -3.87, a PEG ratio of -30.70 and a beta of 0.83. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The firm has a fifty day moving average price of GBX 4.93 and a 200 day moving average price of GBX 8.14.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.